Avalyn Pharma Inc. Common Stock
NASDAQ: AVLN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- NASDAQ Global Market
- Sector
- Healthcare
- Industry
- Medical - Pharmaceuticals
- CEO
- Lyn Baranowski
- Employees
- 50
- Headquarters
- Boston, United States
- IPO year
- 2026
- Market cap
- $1.3B
- Website
- http://www.avalynpharma.com
Loading AVLN…
Loading profile data…Frequently asked questions about AVLN
What does Avalyn Pharma Inc. Common Stock (AVLN) do?
Avalyn Pharma Inc. operates as a biopharmaceutical firm currently in its clinical development phase. The company's primary focus is on creating inhaled pharmaceutical products to manage rare lung conditions, including pulmonary fibrosis and various other interstitial lung diseases (ILDs). Richard Glenn Vincent, Mark W. Surber, and Michael J. Kam...
Where does AVLN trade?
Avalyn Pharma Inc. Common Stock (AVLN) trades on the NASDAQ Global Market.
What sector is AVLN in?
Avalyn Pharma Inc. Common Stock (AVLN) operates in the Healthcare sector, specifically in the Medical - Pharmaceuticals industry.
Who is the CEO of Avalyn Pharma Inc. Common Stock?
Lyn Baranowski is the chief executive officer of Avalyn Pharma Inc. Common Stock (AVLN).
Where is Avalyn Pharma Inc. Common Stock headquartered?
Avalyn Pharma Inc. Common Stock is headquartered in United States.
Does AVLN pay a dividend?
Avalyn Pharma Inc. Common Stock (AVLN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did AVLN go public?
Avalyn Pharma Inc. Common Stock (AVLN) completed its initial public offering in 2026.